Pharmacology, Toxicology and Pharmaceutical Science
Visceral Leishmaniasis
100%
Chagas Disease
85%
Pharmacokinetics
81%
Trypanosoma Cruzi
69%
Mycobacterium Tuberculosis
65%
Infection
61%
Mouse Model
61%
Diseases
59%
Structure Activity Relationship
54%
Antimalarial Agent
51%
Lysine Transfer RNA Ligase
51%
Cytotoxicity
48%
Proteasome
39%
Plasmodium falciparum
37%
Proteasome Inhibitor
34%
Sphingosine 1 Phosphate Receptor
34%
Ponesimod
34%
Protozoon
31%
Pyrimidine
31%
Efficacy Study
27%
Oxidoreductase
25%
Pyrimidine Derivative
22%
Lipophilicity
22%
Cryptosporidiosis
21%
Parasitosis
19%
Piperazine Derivative
17%
Phosphotransferase
17%
Carboxamide
17%
Indole
17%
Target Identification
17%
Quinazolinone Derivative
17%
Drug Market
17%
Indazole Derivative
17%
Naphthyridine Derivative
17%
Tablet
17%
Plasmodium
17%
Cannabinoid Receptor Agonist
17%
Topical Agent
17%
Pharmaceutical Chemistry
17%
Pretomanid
17%
Drug Development
17%
Side Effect
17%
Nagana
17%
Ion Channel
17%
Antimalarial Activity
17%
Phenol
17%
QSAR Study
17%
Drug Concentration
17%
Mycobacterium avium
17%
Cryptosporidium
17%
Keyphrases
Visceral Leishmaniasis
100%
Mycobacterium Tuberculosis (M. tb)
92%
Chagas Disease
85%
Trypanosoma Cruzi (T. cruzi)
69%
Preclinical Candidate
57%
LysR Family
51%
Mouse Model
44%
In Vivo Efficacy
41%
Mode of Action
41%
Metabolic Stability
34%
Causative Agents
34%
Soft Drugs
34%
Sphingosine-1-phosphate Receptor (S1PR)
34%
Protease Inhibitors
34%
2,4-Diaminopyrimidine
34%
Current Treatment
34%
Plasmodium Falciparum
32%
Metabolism
31%
Protozoan Parasites
31%
Structure-activity Relationship
28%
Amino
25%
In Vivo Pharmacokinetics
25%
Potential Treatments
25%
Cryptosporidiosis
25%
Compound 8
25%
In Vivo Activity
22%
Absorption Distribution
22%
In Vivo Clearance
22%
Proteasome Inhibition
22%
Mechanism of Action
22%
Lipophilicity
22%
Phenotypic Screening
22%
Cheminformatics
22%
Leishmania Donovani
21%
Resistant Strains
21%
Structure-based Design
20%
Parasitic Infection
19%
Ponesimod
19%
Esters
19%
Pharmacokinetics
18%
Mouse Infection
18%
Pharmacokinetic Properties
18%
Tuberculosis Drugs
17%
Mercapto
17%
Pyrimidine
17%
Antileishmanial Activity
17%
Cytotoxicity Profile
17%
Spirocycles
17%
MmpL3 Inhibitor
17%
Diphenylpyrimidine
17%